Breaking News Instant updates and real-time market news.

VRX

Valeant

$22.37

-0.405 (-1.78%)

14:14
10/14/16
10/14
14:14
10/14/16
14:14

Wells says Valeant price hikes a reaction to 'disappointing' prescription trends

Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."

  • 16

    Nov

  • 14

    Dec

VRX Valeant
$22.37

-0.405 (-1.78%)

09/19/16
WELS
09/19/16
NO CHANGE
WELS
Price increases could be negative sign, says Wells Fargo
After Valeant increased the list prices of three of its products with combined sales of $1.2M last year, Wells Fargo says further price increases could be forthcoming, and the price increases could indicate that the company feels it needs to raise prices to meet its 2H16 guidance. Noting that the company raised the list price on each of the products by 9.9%, Wells believes that the company could have raised prices by that amount instead of 10% to "stay under the radar of managed care plans and states" looking to prevent double digit price increases. Wells keeps an Underperform rating on the stock.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.

TODAY'S FREE FLY STORIES

07:25
01/23/18
01/23
07:25
01/23/18
07:25
General news
FX Update: The dollar trading mostly firmer »

FX Update: The dollar…

HBIO

Harvard Bioscience

$3.90

-0.05 (-1.27%)

07:25
01/23/18
01/23
07:25
01/23/18
07:25
Conference/Events
Harvard Bioscience to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VMI

Valmont

$169.70

-1.4 (-0.82%)

07:24
01/23/18
01/23
07:24
01/23/18
07:24
Downgrade
Valmont rating change  »

Valmont downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$45.20

-3.65 (-7.47%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Upgrade
Lumentum rating change  »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

MAC

Macerich

$66.00

2.25 (3.53%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Periodicals
Ontario Teachers' in talks with investors on Macerich bid, Bloomberg reports »

Ontario Teachers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Conference/Events
Washington Journal holds discussion on resolving government shutdown »

The Washington…

NFLX

Netflix

$227.58

7.12 (3.23%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HSGX

Histogenics

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics 2.34M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GAIA

Gaia

$11.90

-0.05 (-0.42%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Conference/Events
Gaia management to meet with B. Riley »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:20
01/23/18
01/23
07:20
01/23/18
07:20
General news
Treasury Market Outlook: global yields tracked lower overnight »

Treasury Market Outlook:…

07:18
01/23/18
01/23
07:18
01/23/18
07:18
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

STT

State Street

$108.99

1.38 (1.28%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Hot Stocks
State Street sees Beacon savings realized 18 months ahead of plan by mid-2019 »

In slides ahead of its Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

W

Wayfair

$90.64

2.8 (3.19%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.